(Reuters) – Nearly half of lymphoma patients treated with Gilead Sciences Inc’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to data presented on Saturday. Out of 101 patients teated with Yescarta for ... More »
(Reuters) – Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial. The company said it will apply for U.S. approval for the treatm... More »
(Reuters) – Agios Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration approved its treatment for a type of leukemia, the first targeted drug for patients with a specific genetic mutation. The company plans to launch the drug, Tibsovo, in t... More »
(Reuters Health) – Childhood cancer survivors who get plenty of vigorous exercise may live longer than their counterparts who aren’t very active, a recent study suggests. “In cancer survivors, cancer treatment causes what we consider to be an accelerated aging... More »
(Reuters Health) – Adult survivors of childhood cancer are at risk for serious chronic medical problems, but many of them are not particularly concerned about their future health, a study suggests. In a survey of 15,620 adult survivors of childhood cancer and ... More »
(Reuters Health) – The cost of new anti-cancer drugs increased more than five-fold from 2006 to 2015, but a new analysis suggests that cancer patients and insurers may be getting less for their money. Anticancer medications account for the lion’s share of glob... More »
(Reuters Health) – Some oncologists may be more likely to prescribe certain cancer medicines when they receive payments from the companies that make these drugs, a U.S. study suggests. Researchers examined data on payments drug companies made to doctors in 201... More »
(Reuters Health) – Most Americans aren’t aware of cancer drug shortages that might lead some patients to receive less effective or more toxic treatments, a U.S. study suggests. In a nationally representative survey of 420 adults, just 16 percent said they knew... More »
(Reuters) – More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc’s experimental gene-modifying immunotherapy in a small, early stage study, according to... More »
FILE PHOTO: Monsanto’s research farm is pictured near Carman, Manitoba, Canada August 3, 2017. REUTERS/Zachary Prong/File Photo (This Nov 9 story corrects paragraph 11 to remove phrase at end to show Spiegelhalter did NOT say the possible association with AML ... More »
By Andrew M. Seaman(Reuters Health) – People who want access to the best cancer treatment centers in the U.S. may want to avoid health insurance pla More »
By Carolyn Crist(Reuters Health) – Cancer patients receiving chemotherapy should have all their medications and herbal supplements reviewed by a phar More »
By Lisa Rapaport(Reuters Health) – Comfort care for advanced cancer patients is associated with fewer repeat hospitalizations and more hospice referr More »
Merck & Co Inc said on Tuesday it had got a nod from the U.S. Food and Drug Administration for its already-approved immunotherapy drug Keytruda as a treatment for a type of blood cancer. More »
By Andrew M. Seaman(Reuters Health) – When the human immunodeficiency virus (HIV) is successfully suppressed by medication, people with HIV can’t tr More »
By Madeline Kennedy(Reuters Health) – As cancer drug costs rise, U.S. cancer patients are more likely than other medical patients to struggle with pa More »
FILE PHOTO: Packets of Herceptin sit on a pharmacy shelf in London, Britiain, June 9, 2006. REUTERS/Luke MacGregor/File Photo Treatment with two important cancer drugs is about to get much cheaper in Europe with a cut-price copy of Roche’s blood cancer drug Ri... More »
By Andrew M. Seaman(Reuters Health) – In general, childhood cancer survivors are just as satisfied with their sex lives as people who didn’t have ca More »
Cellectis has won U.S. regulatory approval to run an early clinical trial using its gene edited cell therapy product UCART123 for blood cancers, boosting the French biotech firm’s ambitions in the hot area of cancer research. More »
By Andrew M. Seaman(Reuters Health) – Drugs recently approved around the world to fight cancer increased patients’ overall survival, but benefits va More »
A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash/File Photo An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young a... More »
By Lisa Rapaport(Reuters Health) – – Children who’ve had cancer may be more likely to receive the follow-up care they need in adulthood if their pare More »
By Lisa Rapaport(Reuters Health) – Despite advances that have made treatments safer and more effective, childhood cancer survivors don’t appear to ha More »
By Kathryn Doyle(Reuters Health) – For patients with advanced cancer, palliative care should start early and be an integral part of treatment, not ju More »
A screen displays the share price for pharmaceutical maker AbbVie on the floor of the New York Stock Exchange July 18, 2014. REUTERS/Brendan McDermid AbbVie Inc won the conditional backing of an advisory committee of the European Medicines Agency (EMA) on Frid... More »
(Reuters Health) – U.S. doctors and hospitals throw out almost $3 billion (roughly 2.7 billion euros) in unused cancer drugs each year because the medicines come in supersized single-use packages and excess medicine must be discarded for safety reasons, a rece... More »
